Eikon Therapeutics EIKN

NASDAQ EIKN

$5.35 -0.19 (-3.43%)

At close: Oct 29, 2026 · 4:00 PM EDT

Eikon Therapeutics (EIKN) stock price is $5.35, down 3.43% on the day, as of Oct 29, 2026. It is classified in the Biotechnology industry (Healthcare sector).

Key Stats

Add ratio to table…

About

Eikon Therapeutics Inc is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative medicines for serious unmet medical needs in oncology. The company focuses on three therapeutic areas: immuno responsive cancers requiring enhanced immune stimulation advanced cancers with DNA repair abnormalities and hormonally responsive cancers. It leverages its proprietary single molecule tracking platform to identify validate and optimize drug candidates. Its pipeline includes the TLR 7/8 agonist EIK1001 selective PARP1 inhibitors EIK1003 and EIK1004 the WRN helicase inhibitor EIK1005 and androgen receptor antagonist EIK1006. The firm aims to advance these candidates through clinical trials and potentially commercialize them either alone or in combination with established therapies.

Eikon Therapeutics Inc generates revenue primarily through upfront payments milestone payments and potential royalties from collaboration and licensing agreements. The company has received an upfront payment of $10.5 million to Seven and Eight Biotherapeutics Corp and $0.5 million to Superb Wisdom Limited for the TLR 7/8 agonist license. It also received an upfront payment of $31.5 million to Impact Therapeutics Shanghai Inc for the selective PARP1 inhibitor license. Additionally the company may earn milestone payments of up to $369.6 million from Seven and Eight and Superb Wisdom Limited and up to $181.0 million and $775.0 million from Impact Therapeutics upon achieving development regulatory and commercial milestones. Royalties of high single digit to low teen percentages of net sales are also payable to Impact Therapeutics after commercialization. Since no product has been approved yet the company's current income comes from these agreement payments rather than product sales.

Eikon Therapeutics Inc positions itself as an innovative player in the oncology biotech sector competing with large pharmaceutical firms and other biotechs that pursue similar therapeutic approaches. In the TLR 7/8 agonist arena it faces competitors such as Inimmune Corporation's INI 4001 101 and other agents that target only TLR 7 or TLR 8 and are not administered systemically. For selective PARP1 inhibitors rivals include AstraZeneca's AZD5305 Hengrui's HRS 1167 Hansoh Pharma's HS 10502 Gilead's GS 0201 and CNS penetrant candidates such as Nerviano's NMS 293 and AstraZeneca's AZD9574. In the WRN inhibitor space competitors are Vividion's VVD 214 IDEAYA's IDE275 Nimbus Therapeutics' NDI 219216 and MOMA Therapeutics' MOMA 341. The company's competitive advantages derive from its experienced leadership team headed by Dr Roger M Perlmutter and Dr Roy Baynes, its proprietary single molecule tracking technology platform, and a strategy that blends internal discovery with opportunistic in licensing of promising assets.

Eikon Therapeutics Inc collaborates with several biopharma partners that act as its customers for licensing and development arrangements. Specific partners include Seven and Eight Biotherapeutics Corp Superb Wisdom Limited Impact Therapeutics Shanghai Inc and MSD International Business GmbH which supplies pembrolizumab for combination trials. These relationships provide upfront funding milestone payments and potential royalties upon successful commercialization of the licensed products.

Investment Thesis

▲ Bull case

EIKN's bullish case centers on the untapped potential of its lead candidate EIK1001 in combination with Keytruda, which addresses a critical unmet need in oncology by leveraging biomarker-guided dosing to overcome historical toxicity challenges in immune-stimulating therapies. This approach could unlock superior efficacy and tolerability compared to prior agents in the class, positioning EIK1001/Keytruda as a differentiated regimen for skin cancer indications where current standards of care face limitations in durability and response rates. The anticipated interim analysis in the second half of 2026 represents a near-term catalyst that, if positive, could significantly derisk the program and trigger accelerated development timelines, yet the market appears to be pricing the IPO primarily on current cash burn rather than weighting this impending clinical milestone adequately. Furthermore, EIKN's high-throughput discovery platform, rooted in the Nobel Prize-winning science of co-founder Eric Betzig, offers a sustainable engine for pipeline replenishment beyond EIK1001, creating option value that is not reflected in the current valuation despite the company having already secured over $1 billion in cumulative funding since inception. This platform capability could reduce reliance on external innovation and lower long-term R&D attrition risk, a factor often underestimated by investors focused solely on near-term binary outcomes. The leadership of Roger Perlmutter, whose direct role in Keytruda's development provides unparalleled expertise in navigating complex immuno-oncology pathways and regulatory strategy, adds a layer of execution credibility that is difficult to quantify but materially increases the probability of successful clinical and commercial translation compared to peers lacking such seasoned guidance. Finally, the IPO pricing at the top of the range and successful upsize to 21.2 million shares at $18 per share, raising $381.2 million, indicates strong institutional conviction in the face of a selective biotech IPO environment, suggesting that sophisticated investors see value beyond the headline loss figures and are betting on the inflection point represented by the upcoming EIK1001/Keytruda data readout.

EIKN's bullish case centers on the untapped potential of its lead candidate EIK1001 in combination with Keytruda, which addresses a critical unmet need in oncology by leveraging biomarker-guided dosing to overcome historical toxicity challenges in immune-stimulating therapies. This approach could unlock superior efficacy and tolerability compared to prior agents in the class, positioning EIK1001/Keytruda as a differentiated regimen for skin cancer indications where current standards of care face limitations in durability and response rates. The anticipated interim analysis in the second half of 2026 represents a near-term catalyst that, if positive, could significantly derisk the program and trigger accelerated development timelines, yet the market appears to be pricing the IPO primarily on current cash burn rather than weighting this impending clinical milestone adequately. Furthermore, EIKN's high-throughput discovery platform, rooted in the Nobel Prize-winning science of co-founder Eric Betzig, offers a sustainable engine for pipeline replenishment beyond EIK1001, creating option value that is not reflected in the current valuation despite the company having already secured over $1 billion in cumulative funding since inception. This platform capability could reduce reliance on external innovation and lower long-term R&D attrition risk, a factor often underestimated by investors focused solely on near-term binary outcomes. The leadership of Roger Perlmutter, whose direct role in Keytruda's development provides unparalleled expertise in navigating complex immuno-oncology pathways and regulatory strategy, adds a layer of execution credibility that is difficult to quantify but materially increases the probability of successful clinical and commercial translation compared to peers lacking such seasoned guidance. Finally, the IPO pricing at the top of the range and successful upsize to 21.2 million shares at $18 per share, raising $381.2 million, indicates strong institutional conviction in the face of a selective biotech IPO environment, suggesting that sophisticated investors see value beyond the headline loss figures and are betting on the inflection point represented by the upcoming EIK1001/Keytruda data readout.

▼ Bear case

EIKN's bearish thesis is grounded in the company's deteriorating financial trajectory, highlighted by a widened net loss of $254 million for the nine months ended September 30, 2025, compared to $179 million in the prior year period, reflecting accelerating cash burn despite no corresponding advancement in clinical milestones that would justify such increased expenditure. This trend raises concerns about operational efficiency and the ability to manage expenses as the company scales, particularly given that its most advanced asset EIK1001 remains in a mid-to-late stage trial with no guarantee of success, and the reliance on combination with Keytruda introduces dependency on Merck's continued support and potential shifts in immunotherapy landscape that could diminish the combo's incremental value over time. The biotech sector's current IPO resurgence, while notable, remains highly selective and driven by macroeconomic factors like anticipated rate cuts rather than fundamental improvements in individual company prospects, meaning EIKN's successful debut may reflect favorable market sentiment rather than intrinsic strength, leaving it vulnerable to a sharp re-rating if risk appetite wanes or if the interim analysis for EIK1001/Keytruda in H2 2026 fails to meet expectations. Furthermore, the historical failure of immune-stimulating agents due to systemic toxicity represents a structural risk that biomarker-guided dosing may not fully mitigate, as patient heterogeneity and dynamic immune responses could still lead to unacceptable adverse events in broader populations, potentially limiting label expansion and commercial viability even if the trial meets its primary endpoint. The company's dependence on a single near-term catalyst—the EIK1001/Keytruda interim analysis—creates significant binary risk, with limited diversified pipeline progress disclosed to buffer against failure, and the lack of discussion around alternative indications or monotherapy data during the IPO process suggests narrow optionality. Finally, while the leadership of Roger Perlmutter is frequently cited as a strength, his past success at Merck does not guarantee replication in a smaller, resource-constrained environment like EIKN, where challenges in manufacturing, trial execution, and commercialization may expose gaps in his direct experience, and the premium valuation implied by the IPO pricing may not be sustainable if clinical progress stalls or if competitors develop superior approaches to managing immuno-oncology toxicity.

EIKN's bearish thesis is grounded in the company's deteriorating financial trajectory, highlighted by a widened net loss of $254 million for the nine months ended September 30, 2025, compared to $179 million in the prior year period, reflecting accelerating cash burn despite no corresponding advancement in clinical milestones that would justify such increased expenditure. This trend raises concerns about operational efficiency and the ability to manage expenses as the company scales, particularly given that its most advanced asset EIK1001 remains in a mid-to-late stage trial with no guarantee of success, and the reliance on combination with Keytruda introduces dependency on Merck's continued support and potential shifts in immunotherapy landscape that could diminish the combo's incremental value over time. The biotech sector's current IPO resurgence, while notable, remains highly selective and driven by macroeconomic factors like anticipated rate cuts rather than fundamental improvements in individual company prospects, meaning EIKN's successful debut may reflect favorable market sentiment rather than intrinsic strength, leaving it vulnerable to a sharp re-rating if risk appetite wanes or if the interim analysis for EIK1001/Keytruda in H2 2026 fails to meet expectations. Furthermore, the historical failure of immune-stimulating agents due to systemic toxicity represents a structural risk that biomarker-guided dosing may not fully mitigate, as patient heterogeneity and dynamic immune responses could still lead to unacceptable adverse events in broader populations, potentially limiting label expansion and commercial viability even if the trial meets its primary endpoint. The company's dependence on a single near-term catalyst—the EIK1001/Keytruda interim analysis—creates significant binary risk, with limited diversified pipeline progress disclosed to buffer against failure, and the lack of discussion around alternative indications or monotherapy data during the IPO process suggests narrow optionality. Finally, while the leadership of Roger Perlmutter is frequently cited as a strength, his past success at Merck does not guarantee replication in a smaller, resource-constrained environment like EIKN, where challenges in manufacturing, trial execution, and commercialization may expose gaps in his direct experience, and the premium valuation implied by the IPO pricing may not be sustainable if clinical progress stalls or if competitors develop superior approaches to managing immuno-oncology toxicity.

Peer group

Peer Comparison

Companies in the Biotechnology

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,264.17 Bn	45.84	14.62	49.50 Bn
2	JNJ	Johnson & Johnson	660.04 Bn	41.01	6.64	44.65 Bn
3	ABBV	AbbVie Inc.	521.06 Bn	82.58	8.09	70.82 Bn
4	MRK	Merck & Co., Inc.	370.60 Bn	151.08	5.50	-
5	NVS	Novartis Ag	311.97 Bn	17.91	5.08	-
6	AZN	Astrazeneca Plc	288.69 Bn	27.64	4.92	32.35 Bn
7	AMGN	Amgen Inc	252.29 Bn	28.86	6.62	57.30 Bn
8	GILD	Gilead Sciences, Inc.	213.47 Bn	-58.04	6.89	-

Eikon Therapeutics EIKN

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password